• Artelo Biosciences will present nonclinical ART27.13 neuropathic pain findings today at the IASP 2026 World Congress on Pain in Bangkok.
• Repeated dosing reduced touch and heat sensitivity in male and female animals with paclitaxel-induced peripheral neuropathy.
• The ongoing Phase 2 CAReS trial includes pain endpoints to assess whether these effects translate to cancer patients.
• ART27.13, a once-daily oral treatment under development for cancer-related appetite and weight loss, could also address neuropathic pain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290900PRIMZONEFULLFEED9855638) on October 29, 2026, and is solely responsible for the information contained therein.